文献速递乳腺外科

新发转移性乳腺癌早期局部手术后生存获益:ESME多中心队列研究

Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
PubMed 文献 · Ann Surg · 2021-02-01

该研究基于法国ESME多中心队列,纳入1977例新发IV期乳腺癌且12个月时无进展存活患者,采用12个月landmark分析评估12个月内局部手术对生存的影响。结果显示530例(26.8%)接受手术,手术与更长总生存和无进展生存相关(校正HR分别为0.75和0.72)。

要点

  • 新发转移性乳腺癌12个月内局部手术与更好OS和PFS相关
  • 手术组较未手术组更少≥3个转移灶(90.8% vs 78.2%)
  • 手术组更多接受化疗、HER2靶向治疗和局部放疗

核心结论

  • 在新发转移性乳腺癌诊断后1年内行局部手术与显著更好的总生存和无进展生存相关。

研究设计与样本

  • 多中心回顾性队列研究(法国18家综合癌症中心,ESME数据库,NCT03275311)。
  • 纳入2008年1月至2014年12月间开始治疗的新发IV期乳腺癌患者,共1977例12个月时存活且无进展者进入分析。
  • 采用12个月landmark分析和Cox比例风险模型评估12个月内局部手术对OS和PFS的影响。

主要发现

  • 1977例中530例(26.8%)在12个月内接受了原发乳腺癌手术。
  • 手术组转移灶少于3个的比例高于未手术组(90.8% vs 78.2%,P < 0.0001)。
  • 手术组接受化疗、HER2靶向治疗(89.1% vs 69.6%,P < 0.0001)和局部放疗(81.7% vs 32.5%,P < 0.0001)的比例更高。
  • 多变量分析显示12个月内手术与更长OS和PFS相关,校正HR分别为0.75(95%CI 0.61-0.92)和0.72(95%CI 0.63-0.83)。
  • OS和PFS还受转移部位模式、转移灶数目、组织学亚型和年龄影响。

临床怎么用

  • 对于新发IV期乳腺癌患者,在诊断后1年内行局部手术可能与生存改善相关,但需结合转移负荷、亚型和全身治疗情况个体化决策。

局限性

  • 原文未明确报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to evaluate the impact of local surgery performed during the year after MBC diagnosis on patients' outcomes from a large reallife cohort. SUMMARY BACKGROUND DATA: Locoregional treatment for patients with MBC at the time of diagnosis remains debated. METHODS: Women with newly diagnosed, de novo stage IV MBC and who started MBC treatment between January 2008 and December 2014 in one of the 18 French Comprehensive Cancer Centers were included (NCT03275311). The impact of local surgery performed during the first year on overall survival (OS) and progression-free survival (PFS) was evaluated by the Cox proportional hazards model in a 12 month-landmark analysis. RESULTS: Out of 16,703 patients in the ESME database, 1977 had stage IV MBC at diagnosis, were alive and progression-free at 12 months and eligible for this study. Among them, 530 (26.8%) had received primary breast cancer surgery within 12 months. A greater proportion of patients who received surgery had less than 3 metastatic sites than the no-surgery group (90.8% vs 78.2%, P < 0.0001). Surgery within 12 months was associated with treatment with chemotherapy, HER2-targeted therapy (89.1% vs 69.6%, P < 0.0001) and locoregional radiotherapy (81.7% vs 32.5%, P < 0.0001). Multivariable analyses showed that surgery performed within 12 months was associated with longer OS and PFS (adjusted HR [95%CI] = 0.75 [0.61-0.92] and 0.72 [0.63-0.83], respectively), which were also affected by pattern and number of metastatic sites, histological subtype, and age. CONCLUSIONS: In the large ESME cohort, surgery within 1 year after de novo MBC diagnosis was associated with a significantly better OS and PFS.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Hotton J, Lusque A, Leufflen L, et al. Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort. Ann Surg. 2021. PMID: 33534229. doi:10.1097/SLA.0000000000004767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。